Structure‐Based Design, Synthesis, and Biological Evaluation of Oxadiazole–Morpholine Hybrids as Potent PARP‐1 Inhibitors Inducing Apoptosis in Breast Cancer Cells
Drug Development Research · 2026
DOI: 10.1002/ddr.70346 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Nader R Albujuq und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, School of Science, The University of Jordan, Amman, Jordan. Hauptthemen laut MEDLINE: Oxadiazoles, Poly (ADP-Ribose) Polymerase-1, Breast Neoplasms, Morpholines. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alexander von Humboldt-Stiftung, Philipps-Universität Marburg, University of Jordan.
Abstract (Originalsprache)
Poly(ADP‐ribose) polymerase‐1 (PARP‐1) plays a central role in the repair of DNA single‐strand breaks and represents an established therapeutic target in cancer treatment. In this study, a series of novel oxadiazole–morpholine hybrid compounds was designed and synthesized using a structure‐based drug design approach to target the catalytic domain of PARP‐1. The synthesized compounds were evaluated for their cytotoxic activity against breast and ovarian cancer cells, PARP‐1 inhibitory potency, and apoptosis‐inducing effects. Among the tested compounds, 12a exhibited potent cytotoxic activity against MDA‐MB‐231 cells (IC 50 = 1.23 μM), surpassing the reference drug olaparib (IC 50 = 3.45 μM). Compound 12a also demonstrated strong PARP‐1 inhibitory activity (IC 50 = 0.034 μM), comparable to olaparib (IC 50 = 0.012 μM). Flow cytometric analyses revealed that compound 12a significantly induced apoptotic cell death and altered cell cycle progression. Molecular docking studies suggested plausible binding interactions within the PARP‐1 catalytic site, supporting the observed biological activity. These findings identify oxadiazole–morpholine hybrids as promising scaffolds for further optimization as PARP‐1 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, School of Science, The University of Jordan, Amman, Jordan.
- Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.
- Department of Medicinal Chemistry, Faculty of Pharmacy, Galala University, New Galala, Egypt.
- Department of Pharmacy, Institute of Pharmaceutics and Biopharmaceutics, Marburg University, Marburg, Germany.
- Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.
- Faculty of science, Zarqa University, Zarqa, Jordan.
ORCID-Profile: Khaled M Darwish, Sherif Ashraf Fahmy, Buthaina Hussein, Mohamed S Nafie
Förderung
- Alexander von Humboldt-Stiftung
- Philipps-Universität Marburg
- University of Jordan
Zitieren
APA
Albujuq, N. R., Darwish, K. M., Fahmy, S. A., Hussein, B., Kayed, G. G., Said, M. A., & Nafie, M. S. (2026). Structure‐Based Design, Synthesis, and Biological Evaluation of Oxadiazole–Morpholine Hybrids as Potent PARP‐1 Inhibitors Inducing Apoptosis in Breast Cancer Cells. Drug Development Research. https://doi.org/10.1002/ddr.70346
Vancouver
Albujuq NR, Darwish KM, Fahmy SA, Hussein B, Kayed GG, Said MA, et al. Structure‐Based Design, Synthesis, and Biological Evaluation of Oxadiazole–Morpholine Hybrids as Potent PARP‐1 Inhibitors Inducing Apoptosis in Breast Cancer Cells. Drug Development Research. 2026. doi:10.1002/ddr.70346
BibTeX
@article{Albujuq2026,
author = {Albujuq, Nader R and Darwish, Khaled M and Fahmy, Sherif Ashraf and Hussein, Buthaina and Kayed, Ghada G and Said, Musa A and Nafie, Mohamed S},
title = {Structure‐Based Design, Synthesis, and Biological Evaluation of Oxadiazole–Morpholine Hybrids as Potent PARP‐1 Inhibitors Inducing Apoptosis in Breast Cancer Cells},
journal = {Drug Development Research},
year = {2026},
doi = {10.1002/ddr.70346}
}
EUVIMED